William Blair analyst Ryan Daniels has maintained their bullish stance on TMDX stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ryan Daniels has given his Buy rating due to a combination of factors including the positive trends observed in TransMedics Group’s flight and organ transplant volumes. These metrics have shown a recovery from previous seasonal declines, with flight volumes demonstrating steady momentum as the quarter progresses.
The data indicates that both flight and organ transplant volumes are on track to meet or potentially exceed market expectations for the fourth quarter, provided that December maintains the current pace. This consistent performance supports the outlook for TransMedics Group, justifying the Buy rating assigned by Ryan Daniels.
According to TipRanks, Daniels is a 3-star analyst with an average return of 2.6% and a 41.71% success rate. Daniels covers the Healthcare sector, focusing on stocks such as TransMedics Group, Addus Homecare, and Idexx Laboratories.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $170.00 price target.